Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.

Therapeutic inhibition of the miR-34 family (miR-34a,-b,-c), or miR-34a alone, have emerged as promising strategies for the treatment of cardiac pathology. However, before advancing these approaches further for potential entry into the clinic, a more comprehensive assessment of the therapeutic poten...

Descripción completa

Detalles Bibliográficos

Autores principales:	Bianca C Bernardo, Xiao-Ming Gao, Yow Keat Tham, Helen Kiriazis, Catherine E Winbanks, Jenny Y Y Ooi, Esther J H Boey, Susanna Obad, Sakari Kauppinen, Paul Gregorevic, Xiao-Jun Du, Ruby C Y Lin, Julie R McMullen
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Public Library of Science (PLoS) 2014-01-01
Colección:	PLoS ONE
Acceso en línea:	https://doi.org/10.1371/journal.pone.0090337
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!